Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
The current price of PULM is $2.24, it has decreased 0.66% in the last trading day.
What are the primary business themes or industries for Pulmatrix Inc?
Pulmatrix Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Pulmatrix Inc market cap?
Pulmatrix Inc's current market cap is $8.1M
Is Pulmatrix Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Pulmatrix Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
